TIDMIMM

RNS Number : 6518Z

Immupharma PLC

22 September 2020

22 September 2020

ImmuPharma plc

("ImmuPharma" or the "Company")

Repayment of Convertible Security

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, stated in its announcement on 2 September 2020 that following the placing, both Lind Global Macro Fund, LP ("Lind") and L1 Capital Global Master Opportunities Fund ("L1") had the right to require repayment of a portion of their convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11 June 2020.

The Company announces that Lind has requested repayment of part of its convertible security. The amount to be repaid in accordance with the terms of the convertible security deed is $1,068,762.50 leaving an amount outstanding under the Lind convertible security of $355,112.50 .

L1 has not exercised its right to repayment.

Following the repayment the Company still expects to have sufficient cash resources to fund operations through the end of 2023.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin 
 
    Stanford Capital Partners (Joint Broker)      +44 (0) 203 36 8 3550 
    Patrick Claridge 
    John Howes 
    Bob Pountney                                   +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase III trial for Lupuzor(TM) and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCMZGZLMMMGGZZ

(END) Dow Jones Newswires

September 22, 2020 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Immupharma Charts.